Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06416345

Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
84 (estimated)
Sponsor
Amsterdam UMC, location VUmc · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The majority of people with Parkinson's disease incur Freezing of Gait (FoG), which is not addressed adequately by medication. Cueing is a proven strategy to overcome FoG. The Cue2Walk is a device with automated detection of FoG and provision of rhythmic cues. In this study, the (cost-)effectiveness of the Cue2Walk device as compared to usual care is investigated.

Detailed description

Freezing of gait (FoG) is one of the most common and disabling motor symptoms of Parkinson's disease and is associated with poorer quality of life. However, current pharmacological or even surgical treatments do not address FoG adequately and innovative rehabilitation strategies are needed. Cueing is a proven strategy to overcome FoG episodes and an essential part in the management of FoG. The Cue2Walk, a Medical Device Class I CE-certified leg-worn device, addresses the debilitating effects of FoG episodes at home with 'smart cueing' by combining automatic detection of a freezing episode with manual or automatic rhythmic cues (auditory or vibro-tactile). This study aims to investigate the (cost-)effectiveness of the Cue2Walk device as compared to usual care. This study is a multicenter randomized clinical trial with 2 parallel groups (24-week intervention group and 24-week 'waiting list' group). After 24 weeks, an 8-week naturalistic follow-up will be implemented for the intervention group, while participants in the waiting list group will also receive the intervention, but for 8 weeks. Frequently repeated assessment of outcomes measures will be conducted.

Conditions

Interventions

TypeNameDescription
DEVICECue2Walk24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up
OTHERUsual Care24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment

Timeline

Start date
2025-08-22
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2024-05-16
Last updated
2026-03-16

Locations

2 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06416345. Inclusion in this directory is not an endorsement.